India’s food safety regulator has issued notices to major pharmaceutical, nutrition and e-commerce companies over concerns that certain health supplement claims could mislead consumers about their nutritional benefits. The action, announced on October 8, 2026, involves Dr Reddy’s Laboratories, Nestlé Health Science, Tirupati Wellness, Amazon, Flipkart and Netmeds.
The Food Safety and Standards Authority of India (FSSAI) has asked the companies to explain why regulatory action should not be initiated over alleged violations involving advertising and health-related claims. The regulator’s concerns centre on how the benefits of certain nutritional products have been described on packaging and online marketplaces.
FSSAI Questions Claims About Protein and Muscle Health
The regulator has raised concerns about claims relating to high protein content, lean muscle maintenance, muscle strength, immunity support and energy metabolism. According to FSSAI, the way these benefits were presented could create a misleading impression about the results consumers might expect from the products.
The notices include concerns surrounding Celevida GLP+, a nutritional product associated with Dr Reddy’s Laboratories and Nestlé Health Science. The product has been marketed for nutritional support and lean muscle preservation in connection with GLP-1/GIP therapies, which are used in certain weight-management and diabetes treatments.
FSSAI is examining whether the product’s name, promotional statements and packaging create an inappropriate association between the supplement and these therapies. The regulator has also questioned claims suggesting that the product helps maintain lean muscle mass or supports muscle strength during weight loss.
Another concern relates to the presentation of the product as a source of comprehensive nutritional support. The regulator has questioned whether the claims, including a representation about European imports and purity, could give consumers an inaccurate impression of its qualities or benefits.
Online Marketplaces Also Under Scrutiny
The inclusion of Amazon, Flipkart and Netmeds highlights the regulator’s scrutiny of health-related product listings on digital retail platforms, alongside the companies responsible for the products and their marketing.
Online marketplaces provide consumers with convenient access to nutritional supplements, protein products and other health-related goods. However, claims displayed on product pages can influence purchasing decisions, particularly when buyers rely on advertised benefits to choose products for specific dietary or health needs.
The notices seek explanations from the companies regarding the claims and the manner in which they were communicated to consumers. The companies have been asked to justify why further action should not be taken under the applicable food safety requirements.
The issuance of notices does not, by itself, establish that every allegation has been proven. The companies’ responses and the regulator’s subsequent assessment will determine the next steps in the proceedings.
Separate Food Safety Violations Also Flagged
FSSAI’s announcement also referred to separate enforcement actions involving other businesses. These included action against Nex International in connection with unsafe food concerns and Shreyash Retail Private Limited over the sale of expired or rotten food products.
These cases concern separate alleged violations and should not be confused with the health-claim notices involving Celevida GLP+.
The wider action reflects the regulator’s focus on food safety compliance, accurate product labelling and responsible advertising. For consumers, the issue is particularly relevant when products are promoted with claims involving immunity, muscle preservation or other physiological benefits.
What the Action Means for Consumers
The case underscores the importance of clear, substantiated information when nutritional products are marketed to the public. Claims about protein support, muscle health and specialised dietary needs can influence consumers’ choices, making accurate labelling essential.
As the regulatory process continues, the companies’ explanations will be important in determining whether the disputed claims comply with Indian food safety standards. The outcome could also reinforce expectations for manufacturers, sellers and online marketplaces regarding how health and nutrition benefits are presented to customers.
For now, FSSAI’s notices represent a regulatory challenge to the claims under scrutiny, rather than a final determination against all the companies involved.
